fludarabine + busulfan + melphalan

The combination of fludarabine, busulfan, and melphalan is a conditioning regimen used primarily before hematopoietic stem cell transplantation (HSCT) for various hematologic malignancies. This regimen combines three potent agents with different mechanisms of action to effectively prepare patients for transplantation. ## Description Fludarabine + busulfan + melphalan (FLU/BU/MEL) is a myeloablative conditioning regimen used before allogeneic hematopoietic stem cell transplantation (allo-HSCT). This combination leverages the synergistic cytotoxic effects of these three agents: - **Fludarabine**: A purine nucleoside analog that inhibits DNA synthesis and repair - **Busulfan**: An alkylating agent that cross-links DNA - **Melphalan**: Another alkylating agent with potent anti-leukemic properties The regimen has shown particular efficacy in patients with myeloid malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). Studies have demonstrated that this triple combination provides enhanced anti-leukemic activity compared to dual-agent regimens, with particularly low relapse rates[1][4]. The dosing typically involves: - Fludarabine: 30-40 mg/m² daily for 4 days - Busulfan: Either fixed-dose (130 mg/m²) or pharmacokinetically-guided to target a specific area under the curve (AUC) - Melphalan: 100-140 mg/m² total dose While effective, this intensive regimen is associated with significant toxicities, particularly mucositis and non-relapse mortality[4]. ## Clinical Applications This conditioning regimen has been studied in various hematologic malignancies: - **Myeloid Malignancies**: Shows powerful anti-myeloid leukemia capacity with higher overall survival (OS) and relapse-free survival (RFS) rates compared to standard regimens[4]. - **Lymphoid Malignancies**: Has been investigated in non-Hodgkin's lymphoma, Hodgkin's lymphoma, and multiple myeloma[6][8]. The regimen has demonstrated particular efficacy in high-risk patients and those with refractory disease, though it carries increased toxicity compared to less intensive conditioning approaches. ## Toxicity Profile Common adverse effects include: - Mucositis (62.5% of patients, with 9/35 developing grade III-IV)[4] - Diarrhea (91.07%)[4] - Febrile neutropenia - Veno-occlusive disease (VOD) and transplant-associated thrombotic microangiopathy (TA-TMA) (both at 1.79%)[4] Despite these toxicities, the regimen has shown manageable transplant-related mortality in most studies when used in appropriate patient populations.

Brand names

FludaraAlkeranBusulfexMyleran

Other names

FLU/BU/MELFB/MEL